Monday, October 26, 2020

Covid Roundup: AstraZeneca's Vaccine Data; Moderna's New Deal

Source: Investors Business Daily

By MICHAEL KREY | October 26, 2020

AstraZeneca (AZN) on Monday reported that its Covid-19 vaccine candidate worked as well in older test subjects as it did in younger adults, while vaccine maker Moderna (MRNA) reported its latest supply pact. Shares of MRNA stock dipped while AZN stock moved up.

Late Friday, U.K.-based AstraZeneca announced that the U.S. Food and Drug Administration authorized the restart of its final-phase, or Phase 3, testing for its Covid-19 vaccine candidate. Johnson & Johnson (JNJ) on Friday also announced it was preparing to resume its Phase 3 Covid-19 vaccine trials. JNJ stock edged higher early Monday. 

Both J&J and AstraZeneca put key Covid-19 vaccine tests on hold after a participant in each of their respective trials became seriously ill. AstraZeneca announced its pause on Sept. 6, and said on Sept. 12 that U.K. officials had approved the resumption of Phase 3 trials. In Friday's announcement, the company said it's also resumed Phase 3 clinical trials in South Africa, Brazil and Japan.

On Monday, AstraZeneca posted positive interim data on the safety and effectiveness of its Covid-19 vaccine, AZD1222, in older adults, who in general suffer the most serious illnesses when contracting Covid-19. The company is developing AZD1222 in partnership with the University of Oxford.

"It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher," the company said in an email to Investor's Business Daily. "The results further build the body of evidence for the safety and immunogenicity of AZD1222."

Expects Phase 3 Data This Year

In the email, the company confirmed that it still expects to release Phase 3 test data on its Covid-19 vaccine candidate this year. Before its pause, the AstraZeneca-Oxford team was in the lead in developing a vaccine. They were the first to start Phase 3 clinical trials, in July. By late July, Moderna and the team of Pfizer (PFE) and BioNTech (BNTX) also had begun Phase 3 trials.

Now, Pfizer/BioNTech and Moderna have said they expect to release Phase 3 data next month and soon thereafter seek emergency authorization for their Covid-19 vaccines, assuming their data is positive. U.S. health officials say they are optimistic that one or two Covid-19 vaccines will be approved this year.

Please go to Investors Business Daily to read the entire article.
________


Your health is now all about technology and your RNA can be updated just like software is updated. They are calling your biological RNA the "software of life." Cashing in under cover of the COVID global operation. The Babylonian cult of medicine. 

Welcome to Moderna. We believe mRNA is the "software of life."



A vaccine for everything.



More (Qatar is loaded with cash):

Qatar signs deal to buy Moderna COVID-19 vaccine


Safety concerns of vaccines? Not likely. There is too much money at stake.



There is an entirely different agenda being pursued here by the technologists related to nanoparticles in the injectables likely related to building out their transhumanist goals.



The "corruption is self-evident." Have a look.



No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)
Looking into our circumstances...